Filing Flows › Schrodinger (SDGR) › Q2 2026
Schrodinger (SDGR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Schrodinger (SDGR) reported revenue of $58.9M for the second quarter 2026 (Q2 2026), +8% from a year earlier and +0.5% from the quarter before. Operating margin was -70.6%, net earnings $6.0M (10.1% of revenue).
Schrodinger, Q2 2026: revenue $58.9M (+8% year over year), operating margin -70.6%, net earnings $6.0M, operating cash flow −$34.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $58.9M | +0.5% | +8% |
| Operating profit | −$41.5M | — | — |
| Net earnings | $6.0M | — | — |
| Operating cash flow | −$34.1M | — | — |
What changed
Revenue was $58.9M in Q2 2026, up 8% year over year and up 1% from the previous quarter. Drug discovery was the largest line at 39% of revenue. Drug discovery added $9.0M year over year (up 65%), 219% of the total change. On-premise software declined 41%.
Gross margin was 55.1%, up 7.3 points from Q2 2025. Operating costs exceeded revenue by $41.5M, an operating margin of -70.6%. Operating expenses fell 6% while revenue rose 8%. Net earnings were $6.0M. The effective tax rate was 18.7%. Non-operating items added $48.9M, 665% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$34.1M. Non-cash charges added back $1.5M of depreciation and amortization and $8.8M of share-based compensation. Working capital and other items used $50.3M. Capital expenditures of $362K exceeded it, leaving free cash flow of −$34.4M.
Questions
What was Schrodinger's revenue in the second quarter 2026?
Schrodinger (SDGR) reported revenue of $58.9M for the second quarter 2026 (Q2 2026), +8% from a year earlier and +0.5% from the quarter before.
Was Schrodinger profitable in the second quarter 2026?
Operating loss was $41.5M (-70.6% of revenue) and net earnings $6.0M.
Source: Schrodinger 10-Q on SEC EDGAR.